Quantification of Ultrasonic Scattering Properties of In Vivo Tumor Cell Death in Mouse Models of Breast Cancer  by Tadayyon, Hadi et al.
www.transonc.com
Trans la t iona l Onco logy Volume 8 Number 6 December 2015 pp. 463–473 463Quantification of Ultrasonic
Scattering Properties of In Vivo
Tumor Cell Death in Mouse
Models of Breast Cancer1Hadi Tadayyon*,†, Lakshmanan Sannachi*,†,‡, §,
Ali Sadeghi-Naini*,†,‡, §, Azza Al-Mahrouki*,‡,
William T. Tran‡, Michael C. Kolios†, ¶ and
Gregory J. Czarnota*,†,‡, §
*Physical Sciences, Sunnybrook Research Institute,
Sunnybrook Health Sciences Centre, Toronto, ON, Canada;
†Department of Medical Biophysics, Faculty of Medicine,
University of Toronto, Toronto, ON, Canada; ‡Department of
Radiation Oncology, Odette Cancer Centre, Sunnybrook
Health Sciences Centre, Toronto, ON, Canada;
§Departments of Radiation Oncology, Faculty of Medicine,
University of Toronto, Toronto, ON, Canada; ¶Department of
Physics, Ryerson University, Toronto, ON, CanadaAbstract
INTRODUCTION: Quantitative ultrasound parameters based on form factor models were investigated as potential
biomarkers of cell death in breast tumor (MDA-231) xenografts treated with chemotherapy.METHODS: Ultrasound
backscatter radiofrequency data were acquired from MDA-231 breast cancer tumor–bearing mice (n = 20) before
and after the administration of chemotherapy drugs at two ultrasound frequencies: 7 MHz and 20 MHz.
Radiofrequency spectral analysis involved estimating the backscatter coefficient from regions of interest in the
center of the tumor, to which form factor models were fitted, resulting in estimates of average scatterer diameter
and average acoustic concentration (AAC). RESULTS: The AAC parameter extracted from the spherical Gaussian
model was found to be the most effective cell death biomarker (at the lower frequency range, r2 = 0.40). At both
frequencies, AAC in the treated tumors increased significantly (P = .026 and .035 at low and high frequencies,
respectively) 24 hours after treatment compared with control tumors. Furthermore, stepwise multiple linear
regression analysis of the low-frequency data revealed that a multiparameter quantitative ultrasound model was
strongly correlated to cell death determined histologically posttreatment (r2 = 0.74). CONCLUSION: The Gaussian
form factor model–based scattering parameters can potentially be used to track the extent of cell death at clinically
relevant frequencies (7 MHz). The 20-MHz results agreed with previous findings in which parameters related to the
backscatter intensity (i.e., AAC) increased with cell death. The findings suggested that, in addition to the
backscatter coefficient parameter AAC, biological features including tumor heterogeneity and initial tumor volume
were important factors in the prediction of cell death response.
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Locally advanced breast cancer is characterized as a 5-cm or larger
tumor often with involvement of the axillary lymph nodes and skin
and may include the chest wall. This disease is generally inoperable
and requires upfront chemotherapy treatment for local and metastatic
control. Despite advancements in chemotherapeutics and the
availability of a spectrum of modern drugs including targeted and
systemic drugs, positive tumor response does not always occur. This
makes the early assessment of tumor response to treatment potentially
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be changed to a more effective regimen or a different type of
treatment. This also has the potential benefit of avoiding adverse side
effects and unnecessary costs. Currently accepted methods of response
assessment are based on a reduction in the sum of largest diameters of
target lesions or the largest diameter of unifocal disease [1]. However,
clinically detectable tumor shrinkage does not occur typically until
several weeks to months into treatment. In addition, tumor size
assessments are only usually made using imaging months after the
completion of treatment. In this light, imaging assessments of tumor
biology and biochemistry have led recently to the discovery of novel
biomarkers that can provide earlier indications of tumor response to
therapy [2]. For instance, diffusion-weighted magnetic resonance
imaging (MRI) has been demonstrated clinically to predict the
response of brain tumors as early as 3 weeks after the initiation of
treatment. That method measures changes in the Brownian motion of
water in tumor tissue; water diffusion is thought to increase in
responding tumors due to a decrease in tumor cellularity [3]. In
nuclear imaging, longitudinal positron emission tomography imaging
studies on breast cancer have demonstrated a reduced fluorodeox-
yglucose uptake in responding tumors after one cycle of chemother-
apy [4]. Using a different modality, studies with diffuse optical
imaging investigating breast cancer have demonstrated significant
changes in hemoglobin concentration, water percentage, and
tissue optical index in responding patients as early as 1 week after
the start of chemotherapy [5]. The utility of these modalities in
the clinic, however, remains limited due to the requirement of
contrast agents (MRI), low resolution (diffuse optical imaging),
and limits related to the repeated use of radioactive material
(positron emission tomography). In contrast, ultrasound offers short
image acquisition times, relatively low cost, ionizing-radiation-
free imaging, relatively high-resolution images, and label-free imaging
(no contrast agents required). For these reasons, ultrasound has
received recent widespread attention as a noninvasive therapy
monitoring tool in addition to its well-established diagnostic and
visualization capabilities.
Quantitative ultrasound (QUS) has been used extensively for
various tissue characterization applications, including characterization
of normal and pathological breast tissues [6–8], prostate cancer
detection [9,10], cancerous lymph node detection [11], and
characterization of diffuse liver diseases [12–15]. Such applications
use conventional frequency ultrasound which operates generally in
the 1- to 10-MHz frequency range where one is less concerned with
spatially resolving tissue microstructure and is more interested in the
frequency-dependent backscatter properties of different tissues
(which are affected by tissue microstructure). High-frequency
ultrasound (N20 MHz) offers a higher spatial resolution at the cost
of reduced penetration depth (b2 cm). Its uses include scanning
acoustic microscopy [16], characterization of inflammatory and
neoplastic lesions in excised lymph nodes [17], and detection of cell
death in vivo [18]. High-frequency QUS has been demonstrated to
be a power tool for cell death detection in cancer therapy assessment.
The first high-frequency QUS studies of cell death in cancer cells
induced by a chemotherapeutic agent demonstrated that apoptosis
causes an increase in ultrasound echogenicity [18,19]. These
ultrasound changes were later quantified by system-independent
parameters including midband-fit (MBF) and spectral slope (SS),
both of which demonstrated an increase as a result of cell death [20].
This observation was experimentally determined to be related to thenuclear condensation and fragmentation that occur during apoptosis.
The same pattern of changes in ultrasound parameters was observed
in animal cancer models in vivo, resulting from photodynamic
therapy [21] or radiation therapy [22] of mouse tumor xenografts.
More recently, a study on the low-frequency (7 MHz) QUS
assessment of an animal model of breast cancer treated with
chemotherapy demonstrated that increases in the MBF and spectral
intercept (SI), but not SS, were strongly correlated to increases in cell
death [23]. The MBF, SI, and SS parameters have been used in the
past for other tissue characterization purposes, including the detection
of prostate cancer, malignancies in lymph nodes, uveal melanoma,
and characterizing liver disease [9,11,24,25]. By modeling the
ultrasonic power spectrum as a linear approximation of the acoustic
impedance autocorrelation, Lizzi et al. demonstrated that the SS is
related to the scatterer size, SI is related to scatterer size and acoustic
concentration, and MBF is related to the scatterer size, acoustic
concentration, and attenuation [26]. Furthermore, the fitting of
advanced form factor models to ultrasonic tissue backscatter has
recently permitted the direct estimation of scattering properties of
tissues, including average scatterer diameter (ASD) and average
acoustic concentration (AAC). A form factor is proportional to the
Fourier transform of the spatial autocorrelation of the relative acoustic
impedance between the scatterer and the background. The AAC
parameter is a product of the average number of scatterers per unit
volume and mean square variation in acoustic impedance of the
scatterer and background [27]. These parameters have been
demonstrated to be useful in differentiating between tumor types
in vivo, including sarcoma, carcinoma [28], and fibroadenoma [29].
More recently, a clinical QUS study demonstrated significant
increases in AAC in breast tumors of patients who responded well
to chemotherapy treatment, compared with those who did not
respond well, as early as 1 week after the start of treatment [30].
Various form factor models have been developed to describe tissue
scattering, including the spherical Gaussian model (SGM) and the
fluid-filled sphere model (FFSM) [31]. The SGM describes random
scattering and a continuous variation of acoustic impedance between
the scatterer and its surrounding, and has an impedance autocorre-
lation which follows a Gaussian function. In contrast, the FFSM
describes scattering by randomly distributed fluid-filled spheres, in
which the cell nuclei are considered scatterers and the cytoplasm and
the extracellular material are assumed to be background material.
Good fits have been observed with both models depending from
which kind of tissue ultrasound data were obtained. Regardless,
extensive evidence demonstrates that nuclear material contributes to
backscattered ultrasound signals. There are multiple sources of
experimental evidence suggesting the role of nuclear structure in
potentially influencing significantly ultrasound backscatter signals.
This evidence spans work in vitro, cellular experiments with cellular
structure–modifying agents, investigations of different cell types with
different nuclear sizes, and work with isolated nuclei from viable and
apoptotic nuclei [18,32,33].
To date, very few studies have been reported on cell death
detection using low-frequency ultrasound (b10 MHz) [23,34]. In
addition, linear regression spectral analysis implemented in those
studies provides indirect estimates of tissue scattering properties (i.e.,
ASD and AAC) using a simplified model. In this study, we used an
advanced QUS analysis technique in which scattering models
including the SGM and FFSM were fitted to backscatter coefficient
(BSC) estimates computed from radiofrequency (RF) data from
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scattering properties. First, we compared the two scattering models in
terms of their goodness of fit with measurements, and agreement of
scatterer size estimates with histology. Second, we tracked their
time-dependent cell death responses using the better model
determined in the first step and compared their correlation to
histologically determined cell death extent. Statistical tests were
performed to compare changes in ASD and AAC related to treatment
against those related to tumor progression (control), including
analysis of variance (ANOVA) and post hoc tests. Multiple regression
analyses were performed on changes in ultrasonic scattering properties
and the extent of cell death observed histologically.
Methods
Experimental Procedures
The experimental protocol was approved by the institution's
animal care committee for the humane and ethical use of laboratory
animals. Human breast cancer cell line tumors (MDA-MB231,
American Type Culture Collection, Manassas, Virginia) were
established by injection of 1 × 106 cells in 50 μl of PBS into the
hind legs of severe combined immunodeficiency disease mice and
were permitted to grow to ~1-cm solid tumors. During treatment
and imaging, mice were anesthetized with 100 mg/kg of ketamine,
5 mg/kg of xylazine, and 1 mg/kg of acepromazine (CDMV, St.
Hyacinthe Quebec, Canada). The chemotherapeutic agents paclitaxel
and doxorubicin (100 mg/m2 and 50 mg/m2, respectively) were
injected intravenously through the tail. Pulse-echo imaging was
performed before injection and at a predetermined amount of time
after injection. Experimentation used 20 animals equally divided into
5 groups (n = 4). The first 4 groups were the treatment groups with 4,
12, 24, and 48 hours of wait time after chemotherapy injection,
respectively, and the fifth group served as untreated control tumors
(0 hour).
Low- and high-frequency ultrasound data were acquired using two
imaging systems: a Sonix RP system (Sonix RP, Ultrasonix,
Vancouver, Canada) operating a 7-MHz linear array transducer
(L14-5/38) focused at 1.5-cm depth, with data sampled at 40 MHz,
and the Vevo 770 system (Visual Sonics, Toronto, Canada)
employing a 20-MHz transducer (RMV-710B) focused at 9-mm
depth, with data sampled at 420 MHz. Both systems were used to
collect volumetric data with scan plane separations of ~0.5 mm in the
low-frequency ultrasound and ~0.1 mm in the high-frequency
ultrasound depending on the size of the tumor. Tumor volumes
were estimated by approximating the tumor volume as an ellipsoid
and measuring the three axes (2a, 2b, and 2c) from in vivo
three-dimensional B-mode images obtained using the high-frequency
ultrasound system, and using the formula 43 πabc to estimate the
volume. The images obtained from the high-frequency system were
used for anatomical measurements because that system provided
high-resolution tumor images and more accurate tumor delineation.
Histology Analysis
Histology analysis was performed on excised tumor sections which
were fixed in 5% formalin (volume/volume) in PBS. Each fixed
specimen was sectioned into five slices stained for hematoxylin and
eosin (H&E) and five slices stained for in situ end labeling (ISEL),
with 50-μm spacing. The cell death fraction (CDF) of each tumor
was determined using ImageJ (National Institutes of Health,Bethesda, MD) by manually contouring the ISEL-positive (brown
stain) area and the total tumor area and taking the ratio of the two
areas. The mean CDF for each tumor was obtained by averaging the
CDFs from all five tumor sections. High-magnification images were
obtained using a Leica DC100 microscope with a 40× objective and a
Leica DC100 camera connected to a 2-GHz PC running Leica
IM1000 software (Leica GmbH, Wetzlar, Germany). Areas which
were identified as ISEL positive for CDF calculation were verified
under high magnification to contain more than 50% apoptotic cells.
Mean cell and nucleus sizes were estimated by manually measuring
the diameters of approximately 100 cells and corresponding nuclei in
the ISEL-stained sections under high magnification.QUS Analysis
For analyses, rectangular regions of interest (ROIs) were selected
from 5 to 10 tumor cross-section data sets. These ROIs accounted for
approximately 2/3 of the tumor cross sectional area in ultrasound
images (approximately 5-10 × 5-10 mm in-plane and 5-10 mm
through plane). A sliding window analysis was performed on each
ROI using Hanning-gated RF windows of 2 × 2–mm size for
low-frequency data and 0.62 × 0.62–mm size for high-frequency data,
with 80% overlap between adjacent windows in both axial and lateral
directions. The axial length of the RF segments was selected to cover
approximately 10 wavelengths, which corresponded to the minimum
size required to obtain reliable spectral estimates which were
independent of window length (10 wavelengths) [35]. Each window
spanned 13 RF scan lines in the low-frequency images and 11 RF scan
lines in high-frequency images, respectively. The theoretical BSC was
defined as follows [31]:
σ b kð Þ ¼ nγ
2
9
k4a6F k; að Þ ð1aÞ
γ2≅4
Z scatterer−Zbackground
Zbackground
 2
; ð1bÞ
whereF (k, a) is the form factor, n is average number of scatterers per unit
volume, Z is acoustic impedance, and nγ2 is the AAC, k ¼ 2π fc is the
wave number, and a is the scatterer radius. The measured
BSC was computed by applying the reference phantom
technique to the attenuation compensated normalized power
spectrum, as follows [36]:
σ^ b ¼
Ss fð Þ
Sr fð Þ e
4 αs−αrð Þ RþΔz2ð Þσ^ br ; ð2Þ
where Ss (f ) is the mean sample power spectrum, Sr (f ) is the mean
reference power spectrum, αs and αr are the sample and reference
attenuation functions, R is the distance from the transducer surface
to the proximal edge of the RF window, Δz is the gate length, and
σ^ br is the reference BSC. The mean power spectrum, Ss (f ), of each
RF window was computed by taking the squared magnitude of the
fast Fourier transform of the Hanning-gated RF signal from every
scan line and averaging the result across the scan lines. Spectral
calibration [dividing Ss (f ) by Sr (f )] was carried out to remove
system-dependent effects such as transducer transfer function and
beam forming. The reference material used for spectral calibrations
was a phantom consisting of glass microspheres (5-40 μm)
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BSC, σ^ br , was obtained using pulse-echo technique and planar
reflector (Plexiglas) calibration as described in Ref. [27]. The
attenuation coefficient of the phantom, αr, was 0.15 dB/cm-MHz,
which was determined through an insertion-loss experiment and
fitting a straight line through the attenuation versus frequency data
over the two system bandwidths (3-9 MHz and 10-25 MHz) [6].
The normalized power spectrum was then compensated for
frequency-dependent attenuation using the point-by-point com-
pensation method [31], assuming published attenuation coeffi-
cients, αs, of 2 dB/cm/MHz and 0.6 dB/cm/MHz for skin [38] and
tumor [22], respectively. Scattering properties, including ASD and AAC, were
estimated by theminimumof average squared deviation (MASD) fitting of the
theoretical BSC (σb) and the measured BSC ðσ^ bÞ as follows [31]:
MASD ¼ min 1
m
Xm
i¼1
Xi−X
 !
; ð3aÞ
where
Xi ¼ log σ^ b f ið Þσ b a; f ið Þ
 
ð3bÞ
and
X ¼ 1
N
XN
i¼1
Xi ð3cÞ
This permitted us to generate parametric images of ASD and AAC
over the tumor ROI to assess tumor heterogeneity. Two features were
extracted from the ASD and AAC maps: the mean and standard
deviation [or heterogeneity index (HI)]. We then performed
correlation analysis between histologically determined CDF and the
changes in the means of ASD and AAC images (ΔASD and ΔAAC)
and changes in the HI (standard deviation) of ASD and AAC images
(ΔHIASD and ΔHIAAC) before and after treatment administration.
The mean coefficient of determination, bR2N, and sum of squared
residuals, bχ2N, two metrics which indicate the goodness of fit
between measured and a theoretically derived backscatter coefficient,
were also calculated bearing in mind that these would be affected by
tumor heterogeneity. Finally, QUS parametric images were con-
structed by superimposing color-coded pixels that were mapped to
QUS parameter estimate values and locations associated with the
sliding window locations on the original gray-scale B-mode image of
the tumor [27]. An HI of ASD and AAC that expresses variability of
these parameters over the tumor area (standard deviation of the
parametric image) was calculated as per Nam et al. [39] to reflect
tumor heterogeneity.Statistical Analysis
In order to evaluate of the goodness of fit of each form factor
model, the mean coefficient of determination, bR2N, was computed
from all untreated tumors. Levels of CDF and changes in levels of
AAC were compared among treatment times using a one-way
ANOVA test. This was followed by a post hoc test using Fisher’s least
significant difference (LSD) method to test for statistical significance
in each group relative to the control group. A P value less than .05 was
considered to be statistically significant. The correlations between
CDF and BSC parameters of all tumor samples (N = 17; 3 of the 20animals died midway in the study) were evaluated using multiple
linear regression analysis. All samples were included independent of
group affiliation to have enough samples to obtain a meaningful
correlation. The Pearson product-moment correlation coefficient, r2
metric, was used to evaluate the strength of the correlation. The HI
was used to highlight the inherent tumor heterogeneity in terms of
cell death response and baseline heterogeneity. For analysis of
correlation between QUS and histology (CDF), two scenarios were
considered: multiple regression analysis on the set (ΔAAC, ΔASD,
ΔHIAAC, ΔHIASD) and multiple regression analysis on the set
(ΔAAC, ΔASD, ΔHIAAC, ΔHIASD, Vi). The second scenario
examined the effect of initial tumor volume on the BSC parameters
because it is known that tumor size can have effects on tumor
microstructure and hence on the prediction of cell death response.
Results
Histological Assessment of Treatment Effects
Figure 1 presents H&E- and ISEL-stained sections of representa-
tive control and treatment time groups. Whereas control tumors were
characterized by multiple distinct nucleoli-containing cells and
microvessels, treated tumors were characterized by loss of micro-
vessels, a decrease in the number of cells with distinct nucleoli, and an
increase in the number of cells with condensed nuclei in H&E
sections. Treated tumors also demonstrated a heterogeneous increase
in the area of brown staining in the extracellular space in ISEL
sections. The strong focal stains in the H&E and blue-brown focal
stains in the ISEL sections were consistent in appearance with the
nuclear condensation stage of apoptosis. The brown staining in the
extracellular space in the ISEL was consistent with the appearance of
fragmented DNA and cellular debris associated with late stages of
apoptosis. Both H&E and ISEL sections indicated that, as time
progresses from 0 to 24 hours after the onset of chemotherapy,
tumors changed from a heterogeneous mixture of dead and viable
cells to an almost homogeneous tissue of dead cells. At 48 hours,
tumors appeared to have entered the final stages of cell death marked
by nuclear degradation, as evident from a loss of cells with visible
nuclei. The mean changes in cell and nucleus size with treatment time
are presented in Figure 1E. In general, reductions in cell and nucleus
size were observed resulting from chemotherapy-induced cell death as
time progressed, apparently plateauing at 48 hours. Plots of mean cell
death fraction versus treatment condition are presented in Figure 1F.
Analysis of cell death obtained from ISEL-stained histology images
revealed a monotonic increase in cell death with time from treatment
onset, peaking at 24 hours, after which the cell death content dropped
but remained higher than cell death observed in controls.Tumor Volume Analysis
Plots of mean tumor volume pre- and posttreatment measured by
ultrasound for each experimental condition are presented in Figure 2.
The volumes were estimated based on an ellipsoid model using
B-mode images obtained from the high-frequency system. Addition-
ally, the percent variability in initial tumor volumes was computed as
follows: 74%, 27%, 40%, 20%, and 67% for control, 4-hour,
12-hour, 24-hour, and 48-hour groups, respectively. Percent
variability of the mean initial volume was defined as the standard
deviation of the initial tumor volume across animals divided by mean
initial tumor volume divided by square root of the number of animals
in that group. Initial tumor volumes had large variations (varied as
Figure 1. (A-D) Histology images of representative control (0-hour), 4-hour, 12-hour, 24-hour, and 48-hour chemotherapy-treatedMDA-231
tumors, from left to right, respectively. (A) Low-magnification H&E-stained sections. (B) Low-magnification ISEL-stained sections. (C)
High-magnification H&E-stained section to highlight nuclear material. (D) High-magnification ISEL section to highlight fragmented DNA.
The control tumor features rapidly dividing cells with large nuclei. The treated tumors feature reduced nuclear size (nuclear condensation),
fragmented nuclei, and dead cellular components filling the extracellular space (brown stains). The low-magnification scale bar represents
1 mm. The high-magnification scale bar represents 25 μm. (E) Plots of mean cell and nucleus diameters versus treatment time (0 to 48
hours) estimated from H& E histology sections. Error bars represent standard error of the mean. (F) Plot of the mean cell death fractions
versus time. Error bars represent the standard error across the tumor samples for each time condition. Statistical significance: *P b .05.
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increased slightly in time; however, comparison of pre- and
posttreatment volumes performed through paired t test for each
condition revealed no statistically significant differences (P N .05).
Tissue Microstructure Models
Tumor microstructure was examined microscopically in H&E-
and ISEL-stained sections to identify and characterize structures that
could help understand models of ultrasonic scattering. Figure 1,
column 1, presents H&E and ISEL sections of a representative
control tumor in low-magnification and high-magnification views. In
the H&E sections, tumors appeared to be predominantly composed
of tumor cells (purple-stained nuclei), with infrequent microvessels
(red-pink stained) and connective tissue (cyan-pink stained).Microvessels were only sparsely observed and had a size of 20 ± 2
μm in cross section. The tumor cells dominated the tumor tissue.
Both the H&E and ISEL sections show densely packed cells with high
mitotic indices and large nuclei (18 ± 3–μm diameter) containing
visible nucleoli.
Table 1 lists the average cell size (histology), ASD, AAC, and mean
R2 (bR2N) goodness of fit, as well as mean sum of squared residuals
(bχ2N) obtained from all pretreated tumor BSC at low and high
frequencies using both models. Pretreatment data were used because
they permit the characterization of MDA tumors in terms of
scattering properties without the necessity to consider complex tissue
microstructures which can result from cell death. At the lower
frequency range, both models yielded large ASD values (109 ± 12 μm
for SGM, 95 ± 9 μm for FFSM, P b .05). However, the SGM
Figure 2. Plot of in vivo tumor volumes before (pre) and at
predefined length of time after chemotherapy injection (post).
Percent variability of the initial tumor volumes for each group was
74%, 27%, 40%, 20%, and 67%, for control, 4-hour, 12-hour,
24-hour, and 48-hour groups, respectively.
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bχ2N =1.98 × 10−5) compared with the FFSM (bR2N = 0.07,
bχ2N = 8.07 × 10−4). For this reason, the SGM was used going
forward, and multiple linear regression analysis was performed using
ASD and AAC features extracted from this model. For the
high-frequency data, both models provided smaller ASD estimates
(45 ± 7 μm for SGM and 38 ± 1 for the FFSM), and the FFSM
yielded a statistically significantly smaller ASD compared with the
SGM (P N .05). Both models yielded similar fits (bR2N = 0.08 and
0.06 and bχ2N =5.24 × 10-7 and 5.42 × 10−7 for SGM and FFSM,
respectively). However, to be able to make comparisons between the
two imaging systems, the SGM model was also used for the
high-frequency data going forward with CDF correlation analysis.
Figure 3 presents combined low- and high-frequency plots of
measured BSC and corresponding theoretical BSCs based on the
SGM and FFSM models obtained from one of the treated tumors.
The BSCs were obtained from an RF window at the center of the
tumor ROI at low and high frequencies. Results are shown before and
24 hours after chemotherapy injection. R2 values ranged from 0.55 to
0.71. The FFSM model provided a better fit at high frequency at
pretreatment, whereas no considerable model differences were
observed posttreatment. These values were higher compared with
the values reported in Table 1 because Table 1 reports the mean of
mean R2 where R2 was averaged across all windows in the tumor
ROI which was subsequently averaged over all pretreatment tumors.
However, the R2 reported in Figure 3 was obtained from one RF
window from one animal. Generally, we observed lower R2 values inTable 1. Comparison of ASDs and AACs Estimated Using the SGM and FFSMModels at Low and
High Frequencies (LF and HF) with Mean Histological Measurement of Tumor Cell Size
Cell Diameter
(μm)
18 ± 3
SGM FFSM
ASD AAC R2 χ2 ASD AAC R2 χ2
7 MHz 109 ± 12 5 ± 9 0.21 1.98 × 10−5 95 ± 9 7.35 ± 9 0.07 8.07 × 10−4
20 MHz 45 ± 7 32 ± 19 0.08 5.24 × 10−7 38 ± 1 −11 ± 11 0.06 5.42 × 10−7
R2 (coefficient of determination) and χ2 (sum of squared residuals) are measures of the goodness of
fit of the model BSCs to the measured BSCs. The symbol “±” represents standard deviations of the
parameter over the tumor samples. Estimates were obtained from all tumors (N = 17) before
treatment. Units: ASD = μm, AAC = dB/cm3, R2 = unitless, χ2 = Sr−1cm−1.more heterogeneous tumors which were linked to tumor size. An
increase in the BSC magnitude can be observed from pretreatment to
posttreatment at both frequency ranges. This trend was consistent with
the trend observed in AAC, which is demonstrated in the next section.
Ultrasonic Scattering Properties of Cell Death
Figure 4 presents AAC and ASD images obtained using the SGM
from high- and low-frequency ultrasound imaging, respectively. The
corresponding ISEL section posttreatment is also presented. The
cytotoxic effects of the treatment could be readily visualized
(Figure 4C), demonstrating predominantly brown-stained areas
indicative of cell death. The AAC images demonstrated that AAC
increased considerably as a result of cell death (statistically significant)
at both frequencies, whereas the ASD was less sensitive to cell death at
both frequencies.
ANOVA test revealed that the mean CDF levels were statistically
significantly different among all treatment groups (P = .006), as
demonstrated in Table 2. CDF increased statistically significantly at
24 and 48 hours compared with the control group (post hoc test P b
.05, Table 2). Figure 5 presents mean changes in AAC corresponding
to different treatment conditions (control and 4, 12, 24, and 48
hours) obtained from low- and high-frequency RF data. Results
demonstrated a parallel trend in the AAC changes with treatment
conditions as did the CDF in Figure 1F. Initial observations suggested
that AAC nominally increased proportionally with time, peaking at
24 hours, following the observations for CDF. However, ANOVA
test revealed no statistically significant difference between the means
of the five groups at low and high frequencies, although post hoc LSD
test revealed significant differences between 24-hour and control
groups at low (P = .026) and high (P = .035) frequencies, as indicated
in Table 2. Other tests were used to assess factors as per below where
there were differences.
A stepwise multiple linear regression analysis of CDF versus BSC
parameters (ΔAAC, ΔHIAAC, ΔASD, ΔHIASD) revealed the single
most correlated parameter to be ΔAAC with a correlation (r2) of
0.399. The best multiparameter QUS model was a linear
combination of ΔAAC and ΔHIASD with a correlation of 0.639.
Furthermore, when initial tumor volume (Vi) was added to the model
on the working hypothesis that gross biological changes in tumor
structure associated with tumor growth and size (such as baseline
tumor necrosis and vascular content) may affect data, the correlation
further increased to 0.744 (Table 3A). Stepwise multiple linear
regression analysis of CDF versus tumor volume-normalized BSC
parameters (i.e., BSC parameter × Vi) determined the best predictor
model to be ΔAACVN with r2 = 0.688 (VN stands for volume
normalized). An immediate observation was a considerable increase in
r2 attributed to the normalization of ΔAAC to initial tumor volume
(i.e., from 0.399 to 0.688). Normalization by division of each BSC
parameter by Vi resulted in poorer correlation (r
2 = 0.013). Table 3B
lists the model parameters, their standardized coefficients, and their
individual correlations to CDF for case 1, when Vi was included in
the correlation analysis, and case 2, when all BSC parameters were
normalized to Vi before correlation analysis. In case 1, ΔAAC had the
strongest correlation (r2 = 0.399), followed by Vi (r
2 = 0.197) and
then by ΔHIASD (r2 = 0.068). In case 2, ΔAACVN had the strongest
correlation (r2 = 0.688), and addition of more parameters did not
improve the correlation. Figure 6 presents scatter plots of CDF versus
model predictions with lines of least squares fit. Figure 6A presents
the prediction obtained using the (ΔAAC, ΔHIASD) model, whereas
Figure 3. Combined low -and high-frequency plots of measured BSC and theoretical BSCs based on the SGM and FFSMmodels obtained
from an animal in the 24-hour treatment group. Left: pretreatment. Right: posttreatment. The BSCs were obtained from an RF window at
the center of the tumor ROI. Corresponding R2 goodness-of-fit values are shown below the plots.
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ΔHIASD, Vi) model, which was found to be the optimal QUS model.
Discussions and Conclusions
Ultrasound is widely preferred over currently available breast imaging
modalities due to its relatively low cost, high spatial and temporal
resolution, safety, and independence from external contrast agents.
This study demonstrated that scattering properties can be potentially
used as biomarkers of treatment response–related cancer cell death at
high (20 MHz) and low (7 MHz) ultrasound frequencies.
Examination of tumor histopathology revealed clusters of tumor
cells and microvessels as dominant features which could serve as
potential scatterers of ultrasound with sizes of 18 ± 3 μm and 20 ± 2
μm, respectively. Two scattering properties, ASD and AAC, were
estimated using the SGM and FFSM models to provide insight into
changes in potential scatterer size and scatterer concentration.
Analysis of ISEL-stained histopathology revealed a progressive
increase in cell death extent with time up to 24 hours from treatment
initiation, after which cell death decreased due to nuclear and cellular
degradation (48 hours). Changes in AAC related to cell death were
consistent with changes in surrogate measures of AAC (i.e., MBF and
SI) that were assessed in previous work [22,23] and changes in
backscatter intensity observed in previous in vitro studies [19,20]. In
the study here, the use of a wider analysis bandwidth permitted a
better characterization of the frequency-dependent backscatter of
treated and untreated tumors by fitting advanced scattering models as
opposed to applying a simple linear regression to the power spectrum
within a narrow bandwidth.
Our working model of the ultrasonic scattering properties related
to cell death is that nuclear changes are predominantly responsible for
the increase in AAC. Because AAC is the coefficient of the BSC, it is
related to the backscatter amplitude. Previous in vitro and in vivo
studies suggest that changes in the magnitude and frequency
dependence of ultrasound backscatter with cell death arise from
coincident changes in the nuclear structure of the cell [18,21,32].As tumor structure becomes more complex in association with
tumor growth, there are further complexities which can be linked to
potential sources of ultrasound backscatter. The degree of fit between
the SGM and FFSM models and the measured BSC at both low and
high frequency ranges were consistent with the work of others (R2 =
0.1-0.3) [28]. The poor fits were due to tumor heterogeneity and
small RF window size used. To examine the effect of window size on
BSC fit, a 4-mm window size was examined in addition to the 2-mm
window used in this study. In a randomly selected pretreatment
tumor, it was found that using a 4-mm window resulted in better
model fits than using a 2-mm window (R2SGM and R
2
FFSM were 0.33
and 0.29 for a 4-mm window compared with −0.04 and −0.29 for a
2-mm window, respectively). However, using a 4-mm window would
result in the inability to visualize tumor heterogeneity (no parametric
maps of ASD or AAC), and some small tumors would not
accommodate this window size. Thus, 2 mm was chosen because it
was the largest window size which permits the characterization of
tumor heterogeneity and can accommodate tumors of all sizes in the
study. These previous studies have also demonstrated that the degree
of model fit to the measured backscatter does not reflect the accuracy
of the scatterer size estimates (i.e., agreement between scatterer size
and observed microstructure) and models which fit the measurement
with less than 0.50 bR2N can nevertheless estimate the scatterer
properties reasonably well [28].
The scattering models that were applied in this study were not used
to characterize scattering by individual cells; rather, it is hypothesized
that clusters of predominantly tumor cells with a potential
contribution from microvessels were detected as scatterers. Immu-
nohistochemical examination of tumors 24 hours after therapy
exposure revealed positive staining for cell death covering nearly 60%
of the tumor cross-sectional area. Recall that AAC is related to the
product of scatterer number density and relative acoustic impedance.
Thus, the observed increases in AAC due to cell death may have been
also caused by changes in the acoustic impedance of the scatterers
relative to the background because nuclear fragments were prominent
Figure 4. Pre- and posttreatment (24-hour) images of the central cross section of a sampleMDA-231 tumor which received chemotherapy
treatment. (A and B) High- and low-frequency AAC and ASD images overlaid on the B-mode images, respectively; (C) low- and
high-magnification ISEL-stained histology sections of the tumor. B-mode and low-magnification scale bars represents 2 mm.
High-magnification scale bar represents 25 μm.
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this reason potentially, AAC showed a stronger correlation to cell
death (R2SGM=0.40) compared with ASD (R
2
SGM = 0.00).
An important finding in this study was that initial tumor volume
measurements demonstrated large variations (as high as 74 % of the
mean value). This variation was likely due to differences in tumor
growth and may explain the weak correlation of AAC as a parameter
alone with cell death across tumor samples. As tumors grow beyond 7to 10 mm, in our experience, more vascularization occurs and also
higher baseline levels of necrosis are thought to arise from transient
hypoxia. In the study here, we hence included tumor volume as a
predictive parameter in the QUS model used. Clinical studies have
also used such factors given the complexity of tumor biology linked to
tumor size and the effect of this on response. For example, a breast
MRI study demonstrated that initial tumor volume is significantly
predictive of chemotherapy response of breast cancer patients [40,41].
Table 2. Statistical Significance Tests Comparing the Means of All Treatment and Control Groups
Using the ANOVA Test, and Fisher’s LSD Test Comparing Each Treatment Group to the Control
Group
Parameter ANOVA
Test
Post Hoc Test
Control vs 4 h Control vs 12 h Control vs 24 h Control vs 48 h
CDF 0.006 0.33 0.14 0.001 0.038
AAC (LF) 0.339 0.179 0.128 0.026 0.140
AAC (HF) 0.425 0.101 0.102 0.035 0.068
Results are presented for CDF, ΔAAC (LF), and ΔAAC (HF).
P b .05.
Table 3A. Stepwise Multiple Regression Results
Predictive model Correlation to CDF
ΔAAC 0.399
ΔAAC, ΔHIASD 0.639
ΔAAC, ΔHIASD, Vi 0.744
The second column presents the standardized coefficient of each model, and the third column
presents the model’s correlation to CDF (r2).
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uncharacterized factors such as baseline necrotic cell death and
changes in vascularity associated with preclinical tumor size. These
can influence cell death responses to chemotherapy and often cannot
be controlled in a preclinical setting, The results confirmed that the
correlation between ΔAAC and CDF indeed improved when ΔAAC
was normalized to initial tumor volume (from r2 of 0.399 to 0.688)
and when it was included as an additional biological parameter in the
predictive model (r2 of 0.74).
The reduction in cell size observed histologically and associated
with cell death could not be well detected by scatterer property
estimates. The ASDs estimated by both models were considerably
larger than cells (five times larger at low frequency and two times
larger at high frequency). In a tumor study comparing three form
factor models for characterizing mammary carcinoma and sarcoma
tumors in mouse models, Oelze et al. demonstrated that the SGM
best predicted the size of cell scatterers, although the FFSM provided
better fits to the backscatter power [28]. In contrast, the high-
frequency backscatter data here were fitted better with the SGM
model. This suggests that, depending on the tumor type and the
ultrasound frequency being used, the SGM model may also describe
scattering by an aggregate of cells, rather than individual cells, as was
previously hypothesized by Oelze et al. [28].
Analysis of changes in AAC with treatment indicated greater
increases in AAC estimated from low-frequency data compared with
those estimated from high-frequency data after 24 hours (nearly 2 dB
higher). This observation was consistent with previous findings
in vitro: in the 10- to 30-MHz range, cell samples treated with0
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Figure 5. Plot of ΔAAC versus time from treatment onset. Gray bars
represent mean low-frequency estimates, and black bars represent
mean high-frequency estimates. Error bars represent the standard
error across the tumor samples for each time condition.
*Statistically significant difference from control (P b .05).chemotherapy demonstrated a 5-dB increase in backscatter ampli-
tude, whereas in the 30- to 50-MHz range, a lesser 2-dB increase was
observed [42]. The fact that the ANOVA test revealed no statistically
significant difference among treatment times at both frequencies is
not surprising because of tumor variations in vascularity and baseline
necrosis previously explained which affect QUS parameter estima-
tion. Nevertheless, post hoc tests revealed statistically significant
differences at 24 hours at both frequencies. This was due to the fact
that 24 hours is the time required for cytotoxic drugs to induce
apoptosis on the tumor (as suggested by the highest CDF measured
and as demonstrated in a previous study [43]).
Multiple regression analysis of QUS versus CDF demonstrated the
“best” single parameter based on the experiments conducted to be
ΔAAC and the “best” multiparameter model to be ΔAAC, ΔHIASD,
and Vi. It is believed that ΔHIASD reflects changes in heterogeneity of
the tumor in response to therapy. The improvement obtained by
adding Vi to the regression model suggests that initial tumor volume
affects the BSC parameters and CDF and is an important parameter.
The rationale is that larger tumors often develop necrotic and/or
hypoxic regions and also have a differential vascular content which
could potentially alter the acoustic scattering properties.
In a recent clinical QUS study which examined changes in AAC
and ASD estimated from the FFSM fitting of the BSC from patient
breast tumors, significant increases in AAC were observed as early as 1
week after the start of treatment [30]. However, no corresponding
histopathological data were available during the treatment to compare
AAC changes with microstructural changes in the tumor. Rather,
AAC changes measured during the treatment were compared with
clinical response determined based on tumor size reduction at the end
of the treatment which generally lasts several months. The low- (and
clinically relevant) frequency preclinical study performed here, backed
by high-frequency data, suggests that the increases in AAC observed
clinically during anticancer treatment are likely associated with cell
death response. However, the findings of this study suggest that other
factors such as tumor heterogeneity and initial tumor volume should
also be taken into account when assessing tumor response. Other
studies have begun to assess such factors using image-based texture
analysis to account for tumor heterogeneity [44]. Other studies haveTable 3B. Stepwise Multiple Regression Results for the Two Cases—with and without Tumor
Volume Normalization (Separated by a Horizontal Line)
Predictive Model
Parameter
Standardized Model
Coefficient
Correlation to
CDF
Without normalization ΔAAC 0.765 0.399
ΔHIASD 0.429 0.068
Vi 0.336 0.197
With normalization ΔAACVN 0.829 0.688
The second column presents the standardized coefficient of each model parameter, and the third
column presents the parameter's correlation to CDF (r2).
Figure 6. Scatter plots of CDF versus different predictive models
with lines of least squares fit (A). Predictive model was the linear
combination of AAC and SD(ASD), resulting in R2 = 0.639. (B)
Predictive model was the linear combination of AAC, SD(ASD),
and Vi, resulting in R
2 = 0.744.
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parameters [45].
The fact that SGM form factor fitted the measured BSC better
compared with the FFSM form factor may owe to the theory that the
SGM model better reflects the acoustic impedance autocorrelation
function of the tumor. As mentioned previously, form factors are
proportional to the Fourier transform of the spatial autocorrelation of
the relative acoustic impedance between the scatterer and the
background. A continuous change in acoustic impedance between
the scatterer and its background, which is assumed in the SGM
model, may better reflect the interface between tumor cell clusters and
the extracellular matrix, as opposed to a discrete change in acoustic
impedance described by the FFSM model.
In conclusion, scatterer property-based QUS biomarkers, includ-
ing ΔAAC, ΔHIASD, and Vi, demonstrated a favorable correlation
to cell death extent (CDF). The results of this work are promising
for the development of QUS imaging methods for monitoring
of breast tumor response to anticancer therapy, requiring only astandard clinical US scanner equipped with QUS processing and
imaging software.
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